45% and 95%. The mean was 65% for both types of handable to the Danish population, an ordinary public maternity clinic can handle the collection, and the cost is far less than ling. The cost for the 2-year collection activity was calculated by the hospital administration. Wages Aarhus C, Denmark 5000, renting of space and surveillance ECU 4000. The cost K Füchsel of keeping a person's samples, nitrogen and depreciation on P Petersen nitrogen container will therefore be ECU 10 per year for JH Ebbesen each child when collection is done into small vials, and J Abildtrup ECU 20 when whole blood is kept in plastic bags. This P Schiøler adds up to a lifetime expense in the range of ECU 800 to 1550. Ongoing international work on defining good laboratory practice will require more costly procedures than used here, both for sampling and quality control, stem cell counts, viability and sterility. However, initially autologous collection only requires quality collection, while testing can be left to those cases where the blood is needed later in Acknowledgements life. Furthermore, if collecting becomes part of normal birth practice, the larger market and rationalization will reduce increase. Assuming that the annual number of births is 15 per 1000 (which in Europe is a high number) and taking the European survival curves into consideration, the storage Reference capacity needed after 70 years should level out at 450 large nitrogen tanks with each 2500 donors per 1 million inhabi- 
experience
Here we report 61 patients mobilised with cyclophosphamide (CY) 3 g/m 2 and G-CSF 5 g/kg/day between March 1995 and December 1996. Median age was 45 years High-dose chemotherapy followed by infusion of autolog-(range 18-68) and underlying diagnoses were NHL (30), ous peripheral blood stem cells (PBSC) is now a well estabmyeloma (14), Hodgkin's disease (10), solid tumours (five) lished treatment of haematological and non-haematological and ALL (two). They received a single dose of CY (day malignancies.
1 However, it is still unclear which method 0) in an outpatient setting as per the protocol shown in of mobilising PBSC is most optimal. The combination of Table 1 . G-CSF (Neupogen, Roche, Switzerland) chemotherapy (CT) and recombinant haematopoietic 5 g/kg/day subcutaneously was started 24 h after CY and growth factors (HGF) 2 is most widely used but controcontinued until the last day of leukapheresis (LP). Measureversies still exist concerning the dosage and kind of ments of complete blood counts and CD34 + cells were commobilising HGF and CT agent -these should be effective menced on day 7 after CY administration and LP were in providing sufficient PBSC mobilisation, safe, ie with low initiated when the WBC reached more than 1.0 × 10 9 /l and haematological and non-haematological toxicity, and lastly a distinct population of CD34 + cells could be detected or providing a possible in vivo purging effect. In view of the (from August 1996) when more then 10 CD34 + cells/l increasing number of transplants there is evergrowing were counted. Harvesting proceeded until a target of in the majority of patients with a minimal degree of complications and with good predictability of harvesting. This is in agreement with the data of Mahendra et al 6 who recently showed similar satisfactory results with the same protocol. Table 2 Yield of CD34 + cells
It is clear that some patients need more effective means of PBSC mobilisation -we feel that there is a place for Although our group consists of an unselected patient population with a variety of diseases and different medical histories, we can conclude that the presented PBSC mobilisation regimen is effective, very safe and with good har-3 × 10 6 /kg CD34 + cells (or 5 × 10 6 kg when planning douvesting predicability which make it ideally applicable to an ble transplantation or CD34 + selection) were obtained. A outpatient setting. total of 153 leukaphereses were performed in 60 patients with a median of two (range 1-4) per patient. (Table 2) , ie yield less Czech Republic than 1 × 10 6 CD34 + cells/kg or an insufficient CD34 + count in the peripheral blood for LP initiation, all of them being heavily pretreated and/or irradiated in the past. All aphereses were performed on days 7-13 after CY administration, References with the majority of patients and with the best CD34 + yields in day 8 (Table 3) . There was no procedure-related death 
